This piece cuts through the noise of the BIOSECURE Act by challenging a dangerous assumption: that China's biotech dominance relies on a single chokepoint like TSMC. Jordan Schneider argues that the real threat isn't a monopoly on a specific technology, but a "structural indispensability" woven into the very fabric of global drug development. For busy leaders trying to navigate supply chain decoupling, this distinction is critical; it suggests that the U.S. cannot simply sanction a company out of existence without risking its own medical infrastructure.
The Empire of WuXi
Schneider begins by dismantling the popular "TSMC analogy" that has dominated Washington's thinking. The prevailing narrative treats WuXi AppTec as a singular, irreplaceable node in the biotech stack, much like Taiwan is for advanced chips. Schneider pushes back hard on this. "The TSMC analogy is tempting, since just as TSMC manufactures chips for companies like NVIDIA and AMD, WuXi, instead of discovering and commercializing its own blockbuster drugs, it provides the services... that allow others to do so." However, he notes that the comparison falls apart under scrutiny because "WuXi does not monopolize a single irreplaceable step in the biotech supply chain."
This is a vital correction. The article points out that the top ten contract development and manufacturing organizations (CDMOs) are dominated by firms in U.S. partner nations, with Swiss giant Lonza and American firm Catalent leading the pack. WuXi is merely the third and fifth largest, respectively. Yet, as Schneider observes, "China's specific advantages in biotech look less like control over a single node and more like what it achieved with its manufacturing sector." It is a story of process expertise, cost efficiency, and deep integration. This mirrors the dynamics seen in the rare earth sector, where the leverage comes not just from mining, but from the complex processing capabilities that are hard to replicate quickly.
"WuXi, with its unique corporate structure, is embedded at many layers of the biostack. It has accumulated a structural indispensability that is harder to replace than a single dominant manufacturer would be."
The author's framing here is sharp. It shifts the focus from a "bogeyman" company to a systemic vulnerability. The administration's current playbook, which attempts to map the AI and semiconductor containment strategies onto biotech, may be fundamentally flawed. As Schneider writes, "Washington has increasingly tried to map its AI playbook onto biotech, with early versions of the BIOSECURE Act explicitly targeting WuXi as it would a company like Huawei." This approach ignores the diffuse nature of the biotech landscape. Unlike the concentrated supply chain of semiconductors, biotech is a web of interdependencies.
The "Sea Turtle" Strategy
To understand how WuXi achieved this depth, Schneider traces the company's origins to a unique moment in history: the early 2000s, when cross-border collaboration was the norm rather than the exception. The founder, Li Ge, is described as emblematic of the "sea turtles" (returnees) who bridged the gap between Western science and Chinese labor. "Around 2000, as China prepared to join the World Trade Organization, intellectual property protection in the Chinese pharmaceutical industry significantly improved," Li Ge noted. "I realized that Chinese pharmaceutical companies definitely needed to develop new drugs."
Schneider argues that WuXi's rise was not an accident of statecraft but a market-driven response to the rising cost and complexity of drug development. Western firms needed a pressure valve, and China offered a pool of well-trained, low-cost chemists. The company's strategy was to "follow the molecule" from the lab to commercialization, creating a "strong, diverse, and sticky customer base." This model allowed WuXi to lock in clients by offering an "open-access platform" that eliminated the inefficiency of juggling multiple contractors.
The article highlights a critical statistic that underscores the depth of this entanglement: "A 2024 survey by the Biotechnology Innovation Organization estimates that 79% of US biopharma companies have at least one contract with a Chinese CDMO or CMO." Furthermore, WuXi AppTec alone is estimated to be involved in roughly a quarter of all drugs used in the United States. This level of penetration means that any attempt to sever ties is not a surgical strike but a blunt instrument that could disrupt the entire American healthcare system.
Critics might argue that relying on a foreign entity for such a critical portion of the drug supply chain is an unacceptable national security risk regardless of the business model. However, Schneider's point is that the risk is already baked in; the question is whether the current policy response addresses the reality or just the optics. The article notes that while WuXi has delisted from the NYSE, "an estimated two-thirds of WuXi's revenue comes from U.S.-based customers," making the company's future precarious and the U.S. position vulnerable.
The Scale-Out Paradigm
The piece concludes by examining WuXi's technical capabilities, arguing that their true moat is not a proprietary technology but an integrated ecosystem. "Unlike the TSMC analogy, there is not a WuXi-specific technological moat around their services," Schneider writes. Instead, the advantage lies in the ability to deploy a wide array of frontier technologies—from DNA-encoded libraries to AI-driven automation—under one roof.
Schneider details WuXi's "scale-out" paradigm for biomanufacturing, a method that allows for the rapid expansion of production capacity by adding parallel bioreactors rather than building larger ones. This flexibility is a key reason why the company is so difficult to displace. "Most biotech and pharmaceutical firms lack the resources and expertise to deploy these advanced biotechnologies in-house," the author notes. "But WuXi's comprehensive and integrated platform offers them the access and support needed to compete at the technological frontier."
This analysis suggests that the U.S. cannot simply replicate WuXi's capabilities overnight. The "process expertise" and "deep integration" mentioned earlier are the result of decades of iterative improvement and market feedback. As the article puts it, "A positive feedback loop is born as WuXi aggressively invests in further optimization and expansion, and the platform becomes even more attractive to the next wave of ambitious firms."
"The biotech landscape is much more diffuse than AI. And yet, perhaps because of the TSMC analogies, Washington has increasingly tried to map its AI playbook onto biotech."
Bottom Line
Jordan Schneider's most compelling contribution is the reframing of WuXi from a singular target to a symptom of a broader, systemic dependency that the U.S. helped create. The strongest part of this argument is the evidence that the "chokepoint" narrative is a myth; the real vulnerability is the diffuse, integrated nature of the global biotech supply chain. The biggest vulnerability of the current U.S. approach is its reliance on a containment strategy designed for semiconductors, which may fail to account for the complexity of biological manufacturing. As the administration moves forward, the focus must shift from punishing a single company to building a resilient, diversified ecosystem that can withstand the loss of any single node.